1
|
Luans C, Cardiet I, Rogé P, Baslé B, Le Corre P, Revest M, Michelet C, Tattevin P. Causes and consequences of anti-infective drug stock-outs. Med Mal Infect 2014; 44:470-7. [PMID: 25282606 DOI: 10.1016/j.medmal.2014.07.014] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2014] [Revised: 06/19/2014] [Accepted: 07/22/2014] [Indexed: 11/28/2022]
Abstract
Anti-infective drugs stock-outs are increasingly frequent, and this is unlikely to change. There are numerous causes for this, mostly related to parameters difficult to control: i) 60 to 80% of raw material or components are produced outside of Europe (compared to 20% 30 years ago), with subsequent loss of independence for their procurement; ii) the economic crisis drives the pharmaceutical companies to stop producing drugs of limited profitability (even among important drugs); iii) the enforcement of regulatory requirements and quality control procedures result in an increasing number of drugs being blocked during production. The therapeutic class most affected by drug stock-outs is that of anti-infective drugs, especially injectable ones, and many therapeutic dead ends have recently occurred. We provide an update on this issue, and suggest 2 major actions for improvement: i) to implement a group dedicated to anticipating drug stock-outs within the anti-infective committee in each health care center, with the objectives of organizing and coordinating the response whenever a drug stock-out is deemed at risk (i.e., contingency plans, substitution, communication to prescribers); ii) a national reflection lead by scientific societies, in collaboration with government agencies, upstream of the most problematic drug stock-outs, to elaborate and disseminate consensus guidelines for the management of these stock-outs.
Collapse
Affiliation(s)
- C Luans
- Service de Pharmacie, CHU Pontchaillou, 35033 Rennes Cedex, France
| | - I Cardiet
- COMEDIMS, CHU Pontchaillou, 35033 Rennes Cedex, France
| | - P Rogé
- Service de Pharmacie, CHU Pontchaillou, 35033 Rennes Cedex, France
| | - B Baslé
- Service de Pharmacie, CHU Pontchaillou, 35033 Rennes Cedex, France
| | - P Le Corre
- Service de Pharmacie, CHU Pontchaillou, 35033 Rennes Cedex, France
| | - M Revest
- Service des Maladies Infectieuses et Réanimation Médicale, CHU Pontchaillou, 35033 Rennes Cedex, France; CIC-Inserm 0203, Faculté de Médecine, Université Rennes 1, IFR140, 35000 Rennes, France; Inserm U835, Faculté de Médecine, Université Rennes 1, IFR140, 35000 Rennes, France
| | - C Michelet
- Service des Maladies Infectieuses et Réanimation Médicale, CHU Pontchaillou, 35033 Rennes Cedex, France; CIC-Inserm 0203, Faculté de Médecine, Université Rennes 1, IFR140, 35000 Rennes, France
| | - P Tattevin
- Service des Maladies Infectieuses et Réanimation Médicale, CHU Pontchaillou, 35033 Rennes Cedex, France; CIC-Inserm 0203, Faculté de Médecine, Université Rennes 1, IFR140, 35000 Rennes, France; Inserm U835, Faculté de Médecine, Université Rennes 1, IFR140, 35000 Rennes, France.
| |
Collapse
|